Evolent Health financials
$3.52−3.56%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $652.5M | $496.2M | $468.7M | $479.5M | $444.3M | $483.6M | $646.5M | $621.4M | $647.1M | $639.7M | $556.1M | $511.0M |
| Gross profit | $80.8M | $83.8M | $97.3M | $99.8M | $100.4M | $102.5M | $75.7M | $80.7M | $106.8M | $104.1M | $101.6M | $124.4M |
| Gross margin | 12.4% | 16.9% | 20.7% | 20.8% | 22.6% | 21.2% | 11.7% | 13.0% | 16.5% | 16.3% | 18.3% | 24.3% |
| Operating income | -$9.6M | -$10.6M | -$423.1M | $886.0K | -$1.2M | $4.0K | -$18.6M | -$16.3M | $7.8M | -$13.4M | -$39.4M | -$15.8M |
| Net income | -$28.4M | -$26.6M | -$429.1M | -$26.9M | -$51.1M | -$72.3M | -$30.6M | -$31.2M | -$6.4M | -$25.2M | -$41.4M | -$33.2M |
| Net margin | −4.3% | −5.4% | −91.6% | −5.6% | −11.5% | −14.9% | −4.7% | −5.0% | −1.0% | −3.9% | −7.4% | −6.5% |
| Diluted EPS | $-0.25 | $-0.24 | $-3.85 | $-0.24 | $-0.44 | $-0.63 | $-0.27 | $-0.27 | $-0.06 | $-0.22 | $-0.36 | $-0.30 |
| EBITDA | $13.1M | $11.9M | $21.7M | $27.7M | $23.3M | $25.3M | $33.4M | $14.7M | $38.8M | $26.2M | -$9.4M | $30.2M |
| Operating cash flow | -$9.3M | -$984.0K | $48.8M | $15.8M | -$30.3M | $4.6M | -$26.2M | $18.7M | $30.3M | -$4.0M | $89.4M | $60.5M |
| Free cash flow | -$16.2M | -$7.4M | $41.0M | $6.8M | -$39.1M | -$4.0M | -$32.4M | $12.4M | $23.2M | -$9.3M | $83.3M | $53.7M |
| Diluted shares | 112.5M | 111.9M | 111.6M | 114.1M | 115.9M | 115.3M | 115.0M | 114.9M | 114.7M | 114.1M | 113.7M | 112.3M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $115.7M | $142.0M | $151.9M | $116.7M | $151.0M | $246.5M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $966.5M | $973.5M | $970.5M | $1.06B | $820.6M | $819.3M |
| Total assets | $1.97B | $1.88B | $1.90B | $2.45B | $2.46B | $2.65B |
| Total liabilities | $1.59B | $1.48B | $1.48B | $1.61B | $1.34B | $1.52B |
| Shareholders' equity | $383.2M | $396.4M | $415.2M | $842.2M | $896.0M | $935.5M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology